Tesa/IPA Protocol
Tesamorelin + Ipamorelin GH Secretagogue Blend
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
Mechanism of Action
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Key Benefits
- Synergistic GH release from dual pathways
- More physiological pulsatile GH secretion
- Tesamorelin's proven lipodystrophy benefits
- Ipamorelin's clean side effect profile
- Does not significantly affect cortisol or prolactin
- Single injection convenience
- May improve body composition, sleep, and recovery
Tesamorelin (GHRH analog) + Ipamorelin (GHRP) Complex or non-standard sequence format
Body Composition
- Fat Reduction
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
- Visceral Fat Loss
Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
- Lean Mass Support
Enhanced GH promotes protein synthesis and lean tissue preservation.
Recovery & Wellness
- Sleep Quality
GH secretagogues often improve deep sleep quality.
- Recovery Enhancement
Enhanced GH supports tissue repair and recovery from exercise.
- Anti-Aging Support
Restoring more youthful GH levels may provide anti-aging benefits.
Metabolic Health
- Lipid Profile
Tesamorelin has shown improvements in lipid parameters in studies.
- IGF-1 Optimization
Increased GH leads to increased IGF-1 production.
Subcutaneous injection, typically administered before bed or in the morning on an empty stomach. Evening dosing may enhance natural nighttime GH pulse. Avoid eating 2-3 hours before and 30-60 minutes after injection for optimal results.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol (5/5 blend) | 200-400mcg total | Once daily (evening) | SubQ |
| Enhanced protocol (10/3 blend) | 300-500mcg total | Once daily (evening) | SubQ |
| Twice daily (advanced) | 200-300mcg per dose | Morning and evening | SubQ |
Reconstitution Instructions
- Tesa/IPA vial (5/5mg or 10/3mg)
- Bacteriostatic water (2-3mL)
- Insulin syringes
- Alcohol prep pads
- 1 Clean vial top with alcohol pad
- 2 Add 2mL bacteriostatic water for convenient dosing
- 3 Gently swirl - do not shake
- 4 Solution should appear clear
- 5 Label with date and concentration
- 6 Store refrigerated immediately
- 7 Use within 4-6 weeks
Already contains Tesamorelin - do not add more.
Already contains Ipamorelin - do not add more.
Both Tesamorelin and CJC-1295 are GHRH analogs; combining may cause excessive stimulation.
Already has GHRP pathway covered by Ipamorelin; adding more GHRPs may be excessive.
Both affect GH release; combination may be excessive and affect glucose.
Different mechanisms; can complement for healing with GH support.
Different pathways; some combine for body composition goals.
GH affects glucose metabolism; diabetics should monitor carefully.
Improved sleep quality often noticed first; initial GH response
Enhanced recovery; subtle body composition changes beginning
Noticeable fat loss (especially visceral); improved energy
Full body composition benefits; continued improvements
Common Side Effects
- Injection site reactions (redness, itching)
- Water retention (usually transient)
- Tingling or numbness in extremities
- Joint stiffness
- Increased hunger (Ipamorelin effect)
Stop Signs - Discontinue if:
- Severe injection site reactions
- Significant swelling or edema
- Signs of glucose dysregulation
- Severe joint pain
- Allergic reactions
Contraindications
- Active malignancy (GH may promote tumor growth)
- Diabetic retinopathy
- Pregnancy or breastfeeding
- Pituitary disorders
- Hypersensitivity to components
Good Signs
- Third-party testing confirming both components
- Certificate of Analysis with ratios verified
- Reputable research supplier
- Proper cold chain shipping
Warning Signs
- Tesamorelin is FDA-approved as Egrifta - research blends are not
- Ipamorelin remains investigational
Bad Signs
- No Certificate of Analysis
- Cannot verify Tesamorelin:Ipamorelin ratio
- Discolored or particulate solution
- Tesamorelin FDA Approval for HIV LipodystrophyFDA/Clinical Studies (2010)
Tesamorelin (Egrifta) approved for reduction of excess abdominal fat in HIV patients.
- Tesamorelin Effects on Visceral FatJournal of Clinical Endocrinology & Metabolism
Tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles.
- Ipamorelin Selectivity ProfileGrowth Hormone & IGF Research
Ipamorelin selectively releases GH without affecting cortisol, prolactin, or ACTH.
- GHRH + GHRP SynergyEndocrine Reviews
Combining GHRH and GHRP pathways produces synergistic GH release greater than either alone.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.